Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-305 in relapsed or refractory multiple myeloma and other plasma cell disorders (Phase I/II)
CTR20223084Phase 2Active
- Sponsor
- LaNova Medicines
- Start
- Dec 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LM-305 in multiple myeloma (MM), paraproteinemia, sponsored by LaNova Medicines. Started Dec 2022; status: active.
02
Drugs
LM-305
03
Conditions
multiple myeloma (MM)paraproteinemia
Beyond the preview
Go deeper on CTR20223084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223084.